| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 4,152 | $60.69 | $251,984.88 | -2.6% | +6.6% | -72.9% | |
| Feb 18, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Francis Richard D | President And CEO | Sell | 75,506 | $16.95 | $1,279,660.59 | -26.5% | +2.7% | +105.9% | |
| Feb 18, 2025 | JNJ Johnson & Johnson | Schmid Timothy | EVP, Ww Chair, Medtech | Sell | 403 | $156.15 | $62,928.45 | -2.6% | -1.6% | +58.1% | |
| Feb 14, 2025 | BMY Bristol Myers Squibb Co | Hirawat Samit53 | EVP,Chief Med.offr.,Drug Dev. | Buy | 1,823 | $54.84 | $99,999.97 | +2.9% | -15.0% | +12.7% | |
| Feb 14, 2025 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 2,218 | $116.44 | $258,263.72 | -2.1% | +4.6% | +7.9% | |
| Feb 13, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 35,446 | $879.52 | $31,175,396.35 | - | -17.9% | +19.3% | |
| Feb 13, 2025 | PFE Pfizer Inc | Blaylock Ronald E | Director | Buy | 19,457 | $25.65 | $499,072.05 | +235.8% | -14.1% | +7.6% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Sherwin Stephen A | Director | Sell | 13,831 | $116.69 | $1,613,922.79 | -56.4% | +1.6% | +6.2% | |
| Feb 13, 2025 | MRK Merck & Co., Inc. | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | 6,000 | $85.34 | $512,056.80 | -19.9% | -13.0% | +43.8% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles56 | Director | Sell | 5,844 | $116.69 | $681,914.46 | -0.6% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 1,551 | $116.78 | $181,129.15 | -3.8% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,785 | $116.74 | $208,387.31 | -21.8% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Onyia Jude54 | Chief Scientific Officer | Sell | 2,879 | $116.79 | $336,238.63 | -7.6% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Executive Officer | Sell | 2,558 | $116.85 | $298,908.05 | -0.9% | +1.6% | +6.2% | |
| Feb 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $59.54 | $23,816.00 | -0.5% | +2.0% | +30.7% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 2,558 | $116.86 | $298,923.22 | -3.5% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 2,184 | $116.75 | $254,992.44 | -2.5% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 2,154 | $116.73 | $251,427.64 | -2.4% | +1.6% | +6.2% | |
| Feb 13, 2025 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 1,471 | $116.71 | $171,674.12 | -14.3% | +1.6% | +6.2% | |
| Feb 13, 2025 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 349,340 | $33.92 | $11,848,975.19 | -48.3% | -14.9% | -7.9% | |
| Feb 12, 2025 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 67,687 | $44.71 | $3,026,624.14 | -2.3% | +38.1% | -65.9% | |
| Feb 12, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Sabag Mark | See "remarks" | Sell | 177,626 | $16.25 | $2,886,564.60 | -46.4% | +7.0% | +107.6% | |
| Feb 11, 2025 | PBH Prestige Consumer Healthcare Inc. | Mekhail Adel48 | EVP, Marketing &Sales | Sell | 11,083 | $86.55 | $959,270.90 | -23.2% | +2.4% | -23.3% | |
| Feb 11, 2025 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 326 | $171.18 | $55,804.68 | -2.0% | -7.1% | -26.2% | |
| Feb 10, 2025 | LLY Eli Lilly & Co | Skovronsky Daniel | EVP, CSO &Pres. Lrl &Lly Imm | Sell | 5,000 | $863.21 | $4,316,064.90 | -1.4% | -13.0% | +18.0% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.